May 8, 2023 02:41 PM EDT
Pharma
Manufacturing

Catal­ent de­lays quar­ter­ly call as stock takes an­oth­er dive

Tyler Patchen

News Reporter

Catal­ent said it is de­lay­ing its fi­nan­cial re­sults for the quar­ter, and it now ex­pects to cut $400 mil­lion in net rev­enue guid­ance for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times